Cargando…

Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials

BACKGROUND: Randomised controlled trials (RCTs) provide valuable information and inform the development of harm profiles of new treatments. Harms are typically assessed through the collection of adverse events (AEs). Despite AEs being routine outcomes collected in trials, analysis and reporting of A...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornelius, Victoria, Cro, Suzie, Phillips, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754702/
https://www.ncbi.nlm.nih.gov/pubmed/33353566
http://dx.doi.org/10.1186/s13063-020-04903-0
_version_ 1783626245311823872
author Cornelius, Victoria
Cro, Suzie
Phillips, Rachel
author_facet Cornelius, Victoria
Cro, Suzie
Phillips, Rachel
author_sort Cornelius, Victoria
collection PubMed
description BACKGROUND: Randomised controlled trials (RCTs) provide valuable information and inform the development of harm profiles of new treatments. Harms are typically assessed through the collection of adverse events (AEs). Despite AEs being routine outcomes collected in trials, analysis and reporting of AEs in journal articles are continually shown to be suboptimal. One key challenge is the large volume of AEs, which can make evaluation and communication problematic. Prominent practice is to report frequency tables of AEs by arm. Visual displays offer an effective solution to assess and communicate complex information; however, they are rarely used and there is a lack of practical guidance on what and how to visually display complex AE data. METHODS: In this article, we demonstrate the use of two plots identified to be beneficial for wide use in RCTs, since both can display multiple AEs and are suitable to display point estimates for binary, count, or time-to-event AE data: the volcano and dot plots. We compare and contrast the use of data visualisations against traditional frequency table reporting, using published AE information in two placebo-controlled trials, of remdesivir for COVID-19 and GDNF for Parkinson disease. We introduce statistical programmes for implementation in Stata. RESULTS/CASE STUDY: Visualisations of AEs in the COVID-19 trial communicated a risk profile for remdesivir which differed from the main message in the published authors’ conclusion. In the Parkinson’s disease trial of GDNF, the visualisation provided immediate communication of harm signals, which had otherwise been contained within lengthy descriptive text and tables. Asymmetry in the volcano plot helped flag extreme events that were less obvious from review of the frequency table and dot plot. The dot plot allowed a more comprehensive representation by means of a more detailed summary. CONCLUSIONS: Visualisations can better support investigators to assimilate large volumes of data and enable improved informal between-arm comparisons compared to tables. We endorse increased uptake for use in trial publications. Care in construction of visual displays needs to be taken as there can be potential to overemphasise treatment effects in some circumstances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-020-04903-0.
format Online
Article
Text
id pubmed-7754702
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77547022020-12-22 Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials Cornelius, Victoria Cro, Suzie Phillips, Rachel Trials Research BACKGROUND: Randomised controlled trials (RCTs) provide valuable information and inform the development of harm profiles of new treatments. Harms are typically assessed through the collection of adverse events (AEs). Despite AEs being routine outcomes collected in trials, analysis and reporting of AEs in journal articles are continually shown to be suboptimal. One key challenge is the large volume of AEs, which can make evaluation and communication problematic. Prominent practice is to report frequency tables of AEs by arm. Visual displays offer an effective solution to assess and communicate complex information; however, they are rarely used and there is a lack of practical guidance on what and how to visually display complex AE data. METHODS: In this article, we demonstrate the use of two plots identified to be beneficial for wide use in RCTs, since both can display multiple AEs and are suitable to display point estimates for binary, count, or time-to-event AE data: the volcano and dot plots. We compare and contrast the use of data visualisations against traditional frequency table reporting, using published AE information in two placebo-controlled trials, of remdesivir for COVID-19 and GDNF for Parkinson disease. We introduce statistical programmes for implementation in Stata. RESULTS/CASE STUDY: Visualisations of AEs in the COVID-19 trial communicated a risk profile for remdesivir which differed from the main message in the published authors’ conclusion. In the Parkinson’s disease trial of GDNF, the visualisation provided immediate communication of harm signals, which had otherwise been contained within lengthy descriptive text and tables. Asymmetry in the volcano plot helped flag extreme events that were less obvious from review of the frequency table and dot plot. The dot plot allowed a more comprehensive representation by means of a more detailed summary. CONCLUSIONS: Visualisations can better support investigators to assimilate large volumes of data and enable improved informal between-arm comparisons compared to tables. We endorse increased uptake for use in trial publications. Care in construction of visual displays needs to be taken as there can be potential to overemphasise treatment effects in some circumstances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-020-04903-0. BioMed Central 2020-12-22 /pmc/articles/PMC7754702/ /pubmed/33353566 http://dx.doi.org/10.1186/s13063-020-04903-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cornelius, Victoria
Cro, Suzie
Phillips, Rachel
Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title_full Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title_fullStr Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title_full_unstemmed Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title_short Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
title_sort advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754702/
https://www.ncbi.nlm.nih.gov/pubmed/33353566
http://dx.doi.org/10.1186/s13063-020-04903-0
work_keys_str_mv AT corneliusvictoria advantagesofvisualisationstoevaluateandcommunicateadverseeventinformationinrandomisedcontrolledtrials
AT crosuzie advantagesofvisualisationstoevaluateandcommunicateadverseeventinformationinrandomisedcontrolledtrials
AT phillipsrachel advantagesofvisualisationstoevaluateandcommunicateadverseeventinformationinrandomisedcontrolledtrials